ストックスクリーナーアプリを入手
2.44
2.01%
-0.05
アフターアワーズ：
2.41
-0.03
-1.23%
前日終値:
$2.49
開ける：
$2.44
24時間の取引高:
132.54K
Relative Volume:
0.85
時価総額：
$13.02M
収益：
-
当期純損益:
$-23.92M
株価収益率:
-0.0969
EPS:
-25.1834
ネットキャッシュフロー:
$-22.74M
1週間 パフォーマンス:
+0.41%
1か月 パフォーマンス:
+19.61%
6か月 パフォーマンス:
-80.86%
1年 パフォーマンス:
-88.50%
1日の値動き範囲:
$2.37
$2.46
1週間の範囲:
$2.37
$2.77
52週間の値動き範囲:
$1.79
$28.61
Moleculin Biotech Inc Stock (MBRX) Company Profile
Compare MBRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.44 | 13.29M | 0 | -23.92M | -22.74M | -25.18 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech Stockholders Approve Warrant Share Issuance - TipRanks
Moleculin Biotech shareholders approve warrant issuance, reject name change By Investing.com - Investing.com India
Moleculin Biotech shareholders approve warrant issuance, reject name change - Investing.com
Shareholders at Moleculin (NASDAQ: MBRX) back 6.37M-share warrant plan - Stock Titan
[EFFECT] Moleculin Biotech, Inc. SEC Filing - Stock Titan
Moleculin Biotech | 10-K/A: Annual report (Amendment) - Moomoo
[10-K/A] Moleculin Biotech, Inc. Amends Annual Report - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares via warrants - Stock Titan
Will Moleculin Biotech Inc benefit from geopolitical trends2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Momentum Shift: Will Moleculin Biotech Inc benefit from geopolitical trendsStop Loss & Technical Confirmation Trade Alerts - baoquankhu1.vn
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile - Sahm
Moleculin says Annamycin avoided heart damage in studies - Stock Titan
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile - Bitget
MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Tangible book value per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Advancing Cancer Therapies Amid Clinical Milestones and Biotech Volatility - AD HOC NEWS
Meme Stocks: What are Moleculin Biotech Incs earnings expectations2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN
Total debt per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Clinical-Stage Biotech Focused on Oncology Innovations for North American I - AD HOC NEWS
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - chartmill.com
Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada
Moleculin at Roth Conference: Annamycin’s Market Potential - Investing.com
MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView
MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView
MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada
Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - Minichart
Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - tipranks.com
Moleculin enrolls 45th patient in pivotal AML trial - investing.com
Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative
Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView
Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan
If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan
MBRX SEC FilingsMoleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan
Moleculin Biotech, Inc.: Fundamental Analysis and Financial Ratings | MOL0 | US60855D4088 - marketscreener.com
MBRX Expects Cash Reserves to Fund Operations Through Q3 2026 - GuruFocus
Optimism Surrounds Moleculin's (MBRX) MIRACLE Trial Progress - GuruFocus
Moleculin Biotech Updates Investors with New Corporate Presentation - tipranks.com
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - The Manila Times
Moleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AML - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan
Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView
Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan
Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):